Cantrell Drug Co., an outsourcing drug compounding operation in Little Rock, agreed to an unopposed motion for permanent injunction in a federal lawsuit brought by the U.S. Food and Drug Administration, according to a filing Monday in the case.
Cantrell Drug did not admit or deny any of the government's allegations in the complaint.
The two parties had reached an "agreement in principal" last month to settle legal issues that the company's attorneys said could have put Cantrell Drug out of business.
"It's really a big step forward for Cantrell and the FDA as far as our relationship," said Will McCarley, spokesman for Cantrell Drug. "It's no secret there's been some strife between us. We're excited to see where it takes us and we're excited to be resuming production in the near future."
McCarley called the proposed consent decree a "standard agreement" the FDA reaches with major drug manufacturers.
The FDA sued the pharmaceutical company in federal court last month, seeking to keep it from manufacturing and distributing injectable drugs primarily used in hospitals. The Justice Department accused Cantrell Drug of distributing what the FDA calls adulterated drugs across state lines.
-- David Smith
Business on 04/17/2018